Morphine Decreases Bacterial Phagocytosis by Inhibiting Actin Polymerization through cAMP-, Rac-1-, and p38 MAPK-Dependent Mechanisms

Jana Ninković* and Sabita Roy*†
From the Departments of Pharmacology* and Surgery,† University of Minnesota, School of Medicine, Minneapolis, Minnesota

Morphine increases the susceptibility to opportunistic infection by attenuating bacterial clearance through inhibition of Fcy receptor (FcgR)-mediated phagocytosis. Mechanisms by which morphine inhibits this process remain to be investigated. Actin polymerization is essential for FcgR-mediated internalization; therefore, disruption of the signaling mechanisms involved in this process is detrimental to the phagocytic ability of macrophages. To our knowledge, this study is the first to propose the modulation of actin polymerization and upstream signaling effectors [cAMP, Rac1-GTP, and p38 mitogen-activated protein kinase (MAPK)] as key mechanisms by which morphine leads to inhibition of pathogen clearance. Our results indicate that long-term morphine treatment in vitro and in vivo, through activation of the µ-opioid receptor, leads to an increase in intracellular cAMP, activation of protein kinase A, and inhibition of Rac1-GTPase and p38 MAPK, thereby attenuating actin polymerization and reducing membrane ruffling. Furthermore, because of long-term morphine treatment, FcgR-mediated internalization of opsonized dextran beads is also reduced. Morphine’s inhibition of Rac1-GTPase activation is abolished in J774 macrophages transfected with constitutively active pcDNA3-EGFP-Rac1-Q61L plasmid. Dibutyryl-cAMP inhibits, whereas H89 restores, activation of Rac-GTPase and abolishes morphine’s inhibitory effect, implicating cAMP as the key effector in morphine’s modulation of actin polymerization. These findings indicate that long-term morphine treatment, by increasing intracellular CAMP and activating protein kinase A, leads to inhibition of Rac1-GTPase and p38 MAPK, causing attenuation of actin polymerization, FcgR-mediated phagocytosis, and decreased bacterial clearance. (Am J Pathol 2012, 180: 1068–1079; DOI: 10.1016/j.ajpath.2011.11.034)

Opioid use and abuse steadily increased through the 1990s and has continued to increase over recent years. The 2004 National Survey on Drug Use and Health shows that between 1999 and 2001, the annual incidence of opioid analgesic abuse increased from 628,000 initiates in 1990 to 2.4 million initiates in 2001. It is well established that long-term opioid use or abuse results in severe immunosuppression and increased susceptibility to infection. Long-term morphine use has modulated the innate immune system through a decrease in the proliferative capacity of macrophage progenitor cells and lymphocytes by inhibiting macrophage phagocytic and migratory capabilities, leading to increased risk of sepsis in mice. Similar studies show that morphine’s inhibition of pro-inflammatory cytokines can be overcome by addition of untreated macrophages, suggesting that morphine-induced immunosuppression is due to a deficit in macrophage function. Despite these deleterious consequences of opioid abuse, morphine and other opioid-based pain relievers remain widely prescribed and abused worldwide. There is clearly an urgent need to delineate the underlying cellular and molecular mechanisms by which long-term opiate use or abuse increases susceptibility to bacterial infection. Understanding these mechanisms will allow for the development of novel approaches to treat and prevent bacte-
Morphine Inhibits Phagocytosis via Rac1

**Materials and Methods**

**Reagents**

Heat-killed Escherichia coli particles [E2861: E. coli (K-12 strain) BioParticles, fluorescein conjugate (excitation, 494 nm; emission, 518 nm)], opsonizing reagent (E2870), dextran beads (1-μm yellow-green fluorescent Fluo-Spheres; F8852 (Molecular Probes, Eugene, OR); excitation, 488 nm; emission, 518 nm), and rhodamine phalloidin (R415) were obtained from Molecular Probes. DAPI, cytochalasin D (CytD), H9, DB-cAMP, anisomycin, PD98059, and SB203580 were obtained from Sigma-Aldrich (St. Louis, MO). Antibodies used in fluorescence-activated cell sorter (FACS) analysis included the following: anti-mouse CD64 a and b (phosphatidylethanolamine conjugated, catalogue number 558455; BD Pharmingen, Sparks, MD), anti-mouse F4/80 [fluorescein isothiocyanate (FITC) conjugated, catalogue number 11–4801; eBioscience, San Diego, CA], and anti-mouse CD16/CD32 FITC-conjugated (catalogue number 11-0161; eBioscience). A cAMP detection kit from R&D Systems, Minneapolis, MN (catalogue number KGE002), Rac-GTP G-protein ELISA kits (catalogue number BK125), and the Rac-GTP pull-down kit (catalogue number BK035) were obtained from Cytoskeleton (Denver, CO). Morphine HCl powder and 75-mg slow-release pellets were a gift from the National Institute on Drug Abuse.

**Cells**

The macrophage cell line J774.1 was obtained from American Type Culture Collection (Manassas, VA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin-streptomycin (all from Gibco, Grand Island, NY) under standard conditions for cell growth.

**Animals**

MOR knockout (MORKO) mice (C57BL/6 × 129/Ola genetic background) were produced as previously described by Loh and colleagues. Briefly, a Xhol/XbaI fragment, which spans exons 2 and 3, was replaced with a Neo cassette, followed by the ligation of a thymidine kinase expression cassette to the 3’ end of this segment. Wild-type (WT) mice (B6129PF1/J), aged 8 weeks, were obtained from the Jackson Laboratory (Bar Harbor, ME). Animal studies have been reviewed and approved by the University of Minnesota Institutional Animal Care and Use Committee.

**Primary Macrophages**

Primary peritoneal macrophages were obtained from WT or MORKO male mice aged 6 to 8 weeks; peritoneum was lavaged. The cells were collected and plated in 96-well plates in serum-free media for 30 minutes; non-adherent cells were washed with PBS; and remaining adherent macrophages were maintained in enriched DMEM, as previously described, with or without 1 μmol/L...
morphine, where appropriate (to avoid morphine withdrawal), and used for further experimentation.

**Long-Term Morphine Treatment**

For all *in vitro* experiments, 1 μmol/L morphine HCl was added overnight (18 hours). For studies involving morphine treatment *in vivo*, mice administered morphine were implanted with 75 mg of slow-release morphine or placebo pellets for 72 hours. During the extraction of peritoneal cells from morphine-treated WT or MORKO mice, 1 μmol/L morphine was maintained in all PBS and media used in the experiment to prevent withdrawal. Concentrations used in the *in vitro* paradigm were chosen to closely replicate morphine plasma levels (11 to 1440 ng/mL), which are present in patients undergoing morphine sulfate treatment (2.5 to 90 mg every 4 hours), as well as mice after 72-hour implantation with 75-mg morphine pellets.

**In Vivo Phagocytosis Assay**

Mice were treated *in vivo* with morphine (as previously described), and 30 minutes before sacrifice, they were injected with heat-killed, FITC-labeled *E. coli* Bioparticles. Macrophages were collected from peritoneal lavage (as previously described) and washed with 50% trypan blue to extinguish fluorescence of noninternalized particles. Cells were plated in 96-well plates, left to adhere for 30 minutes in serum-free DMEM, washed, stained with DAPI, and quantified using the fluorometric assay.

**Fluorometric Assay**

Cells were plated in 96-well plates (10,000 cells per well), treated with morphine, and cultured overnight in standard growing conditions (37°C, 10% CO₂, 80% Rh). The following day, fluorescent (FITC-conjugated) opsonized dextran (OPDex) beads or heat-killed opsonized (HKO) *E. coli* was added (1:20, cell:bacteria/bead ratio). Beads or bacteria were opsonized with IgG opsonizing reagent (Invitrogen) for 1 hour at 37°C, according to the manufacturer’s instructions. Phagocytosis was conducted at varied time points and was stopped by addition of trypan blue, which extinguishes fluorescence of noninternalized particles. Cells were washed two times with PBS and stained with DAPI. Fluorescence was recorded using a fluorescence plate reader (FLUOstar Omega; BMG-Labtech, Offenburg, Germany) at an excitation of 485 nm and an emission of 520 nm (FITC) and an excitation of 355 nm and an emission of 460 nm (DAPI). Data were quantified as follows: Phagocytic Index = FITC/DAPI [both given in relative fluorescence units (RFUs)], indicative of particle fluorescence per cell. Actin polymerization experiments, cells were treated similar to that previously described, washed, fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and stained with rhodamine phalloidin (Invitrogen), according to the manufacturer’s protocol. After rhodamine, cells were stained with DAPI and fluorescence was measured using the fluorescence plate reader. Actin polymerization was quantified as ratio of rhodamine (RFU) (excitation, 544 nm; emission, 590 nm)/DAPI (RFU), indicative of actin polymerization per cell. Data were expressed as percentage of vehicle control.

**Confocal Microscopy**

Following the same treatment as previously described, cells were stained with rhodamine phalloidin according to the manufacturer’s instructions. Images were taken using a Nikon inverted confocal microscope (model Ti-E eclipse 100) and a Roper camera (model Cool-snap HQQ) (both from Nikon Instruments, Elgin, IL) at ×60, with additional digital magnification. Images shown are the flattened sum of 15 cross sections.

**Pull-Down and GLISA Assays**

The J774 cells were plated at 500,000 cells per 10 mL of supplemented DMEM (10-cm Petri dish) and cultured for 2 days. On the second day, morphine was added; on the third day, cells were treated with OPDex beads (1:20 ratio) for 30 minutes. Cells were washed, collected, and analyzed according to the manufacturer’s instructions. Briefly, cell lysates were incubated with PAK-PBD beads and allowed to pull down the PAK-PBD/GTP-Rac complex. The amount of activated Rac1 is determined by using Western blot analysis with a Rac1-specific antibody. GTPyS is a nonhydrolyzable GTP analog used as a positive control, and GDP is used as a negative control. Samples analyzed via GLISA assay were prepared as previously described. Protein, 0.7 μg/μL, was added per well; Rac-control protein, 0.2 μg/μL, was used as a positive control.

**Plasmid Transfection**

Addgene plasmid 12981:pcDNA3-EGFP-Rac1-Q61L and pcDNA3-Flag M KK6(glu) were obtained from Addgene (Cambridge, MA), donated by Dr. Gary Bokoch (Scripps Research Institute, La Jolla, CA) and Dr. Roger Davis (University of Massachusetts Medical School, Worcester, MA), respectively. The plasmids were transfected using FuGene reagent (catalogue number 04-709-705-001; Roche, Basel, Switzerland), according to the manufacturer’s protocol. The next day after the transfection, cells were collected, plated, and treated with 1 μmol/L morphine overnight and HKO *E. coli* (Texas Red), as previously described.

**Results**

**Long–Term Morphine Inhibits Macrophage Phagocytosis in Vitro and in Vivo**

Macrophages play a crucial role in morphine–induced immunosuppression. Because morphine has been implicated in increased susceptibility to infections by extracellular pathogens and FcgR is the key phagocytic receptor for clearance of extracellular pathogens, we...
investigated how morphine modulates FcgR-mediated phagocytosis.

To determine the effects of long-term morphine treatment on bacterial clearance mediated by FcgR, macrophages (cell line J774) undergoing long-term morphine treatment (1 µmol/L overnight) were allowed to phagocytose live opsonized green fluorescent protein (GFP)--tagged E. coli for 30 minutes. After extensive washing, fixation (4% paraformaldehyde), and permeabilization (acetone), cells were stained with rhodamine phalloidin (red, actin) and DAPI (blue, nucleus); analyzed via confocal microscopy (Figure 1A); and quantified for pixel density using ImageJ software. Images were quantified for pixel density using ImageJ software.

**Figure 1.** Long-term morphine leads to inhibition of FcgR-mediated phagocytosis by the J774 macrophage cell line. A: After undergoing long-term morphine treatment (1 µmol/L overnight) and 30-minute incubation with live opsonized GFP-tagged E. coli, J774 cells were fixed, stained, and analyzed via confocal microscopy using Nikon EZ-C1 3.0 software. Original magnification, ×600. Scale bar = 10 µm. Red indicates rhodamine (actin polymerization), GFP, E. coli, DAPI, nucleus. Images were quantified for pixel density using ImageJ software. B: Phagocytic index = GFP pixel density/DAPI pixel density. C: J774 cells were treated with 10 µmol/L naltrexone (Sigma-Aldrich) 2 hours before overnight morphine treatment, both were maintained overnight, and phagocytosis was examined the next day using fluorometric analysis, after a 60-minute incubation with OPDex beads. D: After 72 hours of in vitro morphine treatment, in vitro phagocytosis was examined 30 minutes after the i.p. injection of HKO E. coli (WT and MORKO mice). The data illustrate the average phagocytic index for five mice for each treatment.

To avoid withdrawal, morphine was maintained in washes and media were used during the macrophage extraction process (for mice treated with morphine in vivo). Phagocytosis was assessed using fluorometric analysis. E and F Cells undergoing morphine/vehicle treatment and phagocytosis of HKO E. coli (Texas Red conjugated), recorded in Supplemental Video S1 (available at http://ajp.amipathol.org), were quantified for internalization, where the phagocytic index is defined as the intensity of red fluorescence per cell (and expressed as percentage of vehicle control) (E) or cell elongation (defined as change in length = longest length - shortest length observed in 30 minutes of phagocytosis) (F). Fifteen cells per treatment were recorded using Nikon NIS Elements AR 3.2 software.

**Figure 1D.** Phagocytic index (% control) for morphine treatment vs. vehicle. **P < 0.01 and ***P < 0.001.

We next investigated the effect of *in vivo* long-term morphine treatment on phagocytosis using an *in vivo* phagocytosis assay (as described in Materials and Methods). WT and MORKO mice were implanted with slow-releasing 75-mg morphine or placebo pellets. Thirty minutes before sacrifice, mice were i.p. injected with HKO E. coli. Peritoneal lavage cells were washed in trypan blue to extinguish fluorescence of noninternalized HKO E. coli, and peritoneal macrophages were isolated using standard protocols. Phagocytosis of HKO E. coli was inhibited in primary peritoneal macrophages isolated from morphine-treated WT mice. This effect was abolished in peritoneal macrophages harvested from MORKO mice (Figure 1D). These data indicate that the phagocytic ability of primary peritoneal macrophages is significantly reduced in mice undergoing *in vivo* long-term morphine treatment and is mediated by MOR, as shown by the lack of mor-
Phenomen-induced inhibition in macrophages extracted from the MORKO mice. These findings were further confirmed using time-lapse imaging, during which we observed that, over 60 minutes of phagocytosis of Texas Red-labeled HKO E. coli (Invitrogen), J774 cells that underwent long-term morphine treatment displayed significantly impaired bacterial clearance (Figure 1E; see also Supplemental Video S1 at http://ajp.amjpathol.org) and reduced cell elongation (Figure 1F; see also Supplemental Video S1 at http://ajp.amjpathol.org).

To examine if morphine’s attenuation of phagocytosis is due to modulation of FcgR surface expression, we conducted FACS analysis of morphine-treated J774 macrophages (Figure 1, G and H). FACS analysis determined that expression of key phagocytic receptors, such as FcgR1 a/b (Figure 1G), FcgR2, and FcgR3 (Figure 1H), was not altered in J774 cells after morphine treatment, indicating that morphine modulation of FcgR is not involved in morphine-induced inhibition of phagocytosis. Based on this evidence, we speculate that cross talk between the MOR and FcgR signaling pathways must be downstream from the FcgRs. Considering recent reports24–26 that indicate that morphine induces macrophage apoptosis, the effects of morphine on cell viability were investigated. An MTT assay was used to quantify cell viability after morphine treatment or OPDex bead exposure (see Supplemental Figure S1D at http://ajp.amjpathol.org). The data indicate that, in this model, there were no changes in cell viability with morphine or OPDex bead treatments.

Together, these findings show that morphine-induced inhibition of phagocytosis observed in the macrophage cell line J774 can be replicated in primary macrophages, and that morphine’s inhibitory effects on phagocytosis are not due to changes in FcgR expression or changes in cell viability. Furthermore, we also demonstrate, via QT-PCR, that primary and J774 macrophages display comparable MOR and FcgR expression levels, expressed as ratio of MOR/FcgR (see Supplemental Figure S1H at http://ajp.amjpathol.org). Therefore, all subsequent mechanistic studies were conducted in J774 cells using OPDex beads.

**Long-Term Morphine Treatment Inhibits Phagocytosis by Inhibiting Actin Polymerization**

Remodeling of the actin cytoskeleton is a prerequisite for FcgR-mediated phagocytosis.27,28 Actin polymerization enables formation of the phagocytic cup, leading to the subsequent internalization of the phagocytic target and phagosome maturation.28 In our initial studies using time-lapse imaging (see Supplemental Video S1 at http://ajp.amjpathol.org), we observed that cells undergoing long-term morphine treatment, in addition to a reduced ability to internalize bacteria, displayed profound defects in cell motility and elongation (Figure 1F) during phagocytosis of HKO E. coli. When exposed to long-term morphine treatment, cells were more rounded and had decreased motility when compared with the vehicle-treated cells, which were more spindlelike and had greater cell motility (see Supplemental Video S1 at http://ajp.amjpathol.org). These observations of changes in phagocytosis and cell elongation indicate that morphine may play a role in modulation of actin polymerization.

To examine the function of actin polymerization in morphine-mediated attenuation of phagocytosis, we used CytoD, a known inhibitor of actin polymerization. As expected, pretreatment by CytoD (10 μmol/L) abolished J774 macrophage phagocytosis of both vehicle- and morphine-treated cells (Figure 2A). The dramatic decrease in the phagocytic rate after CytoD treatment confirms the essential role of actin in FcgR-mediated phagocytosis.

Confocal microscopic analysis of cells undergoing phagocytosis after long-term morphine treatment exhibited a reduction in membrane ruffling (Figure 2B), as well as changes in lamellipodial protrusions (Figure 2B) compared with vehicle controls. Furthermore, morphine-treated cells displayed a reduction in overall intensity of rhodamine phalloidin staining (Figure 2B), suggesting a decrease in actin polymerization. A similar inhibition with morphine treatment was observed in fluorometric analysis, in J774 cells treated with morphine for a long time (see Supplemental Figure S1D at http://ajp.amjpathol.org) exposed for 60 minutes to OPDex beads (Figure 2C). Morphine modulation of actin polymerization was only observed with opsonized particles (see Supplemental Figure S1E at http://ajp.amjpathol.org), and antagonized by naltrexone pretreatment (Figure 2C). The role of MOR in morphine’s inhibitory effect on actin polymerization was further confirmed using macrophages isolated from MORKO mice. Morphine’s inhibition of actin polymerization, observed in WT macrophages (Figure 2D), was abolished in primary macrophages extracted from MORKO mice (Figure 2E). These data indicate the crucial involvement of classic opioid receptors (namely, MOR) in modulation of actin polymerization.

Phagocytosis was also analyzed after synchronization using cytopin, which allowed for phagocytosis to begin at a fixed time. Cells were treated with morphine (previously described), and immediately after the addition of OPDex beads, they were centrifuged to synchronize the beginning of phagocytosis (with the starting point determined as time 0 minutes after centrifugation). Actin polymerization is rapidly increased at early time points after synchronization. Results show that morphine does not merely delay, but rather inhibits, the process of phagocytosis (Figure 2F) and actin polymerization (Figure 2G) at each time point.

**Long-Term Morphine Inhibits Actin Polymerization by Modulating Activation of Rac-GTPases**

Rho GTPases, such as Rac and Cdc42, play an essential role in actin polymerization by modulating membrane ruffling and lamellipodial protrusions.29 Because morphine leads to defects in cell elongation (Figure 1F) and membrane ruffling (Figure 2B), we investigated if long-term morphine inhibits activation of Rho GTPases.
Long-term morphine treatment significantly inhibits activation of Rac1-GTPase in cells undergoing phagocytosis of OPDex beads, as shown in the pull-down assay (Figure 3A). In contrast, Cdc42 (see Supplemental Figure S1F at http://ajp.amjpathol.org) was only marginally affected by long-term morphine treatment; therefore, we focused on Rac1-GTPase in all of our subsequent studies.

To further establish the role of Rac1-GTPase in this process, we examined the effects of morphine on J774 cells expressing constitutively active Rac1. Cells transfected with Rac1-Q61L, in the absence of phagocytic stimuli, displayed a distinct increase in cell spreading and actin polymerization, which was absent in the pcDNA3 control (see Supplemental Figure S1G at http://ajp.amjpathol.org). These observations are in accordance with the literature because Rac1-GTPase activation has been implicated in increased formation of lamellipodia and membrane ruffling. Therefore, it was not surprising that constitutive activation of Rac1-GTPase resulted in increased actin polymerization, despite the absence of phagocytic stimuli.

By using both fluorescence microscopy (Figure 3B) and fluometry (Figure 3C), we demonstrate that morphine treatment resulted in inhibition of opsonophagocytosis in control pcDNA3-transfected cells (Figure 3B), whereas cells transfected with constitutively active Rac1-GTPase (pcDNA3-EGFP-Rac1-Q61L plasmid) rescued morphine’s inhibitory effect (Figure 3B). Similarly, the transfection of constitutively active Rac1-Q61L plasmid abolished morphine-mediated inhibition of actin polymerization (Figure 3D).

Because Rac1-Q61L expression can also increase particle uptake through macropinocytosis, independent of FcgR, we examined if our findings are potentially confounded by this process. The role of macroinocytosis was tested by comparison of internalization of opsonized with unopsonized particles by cells expressing Rac1-Q61L plasmid. Cells phagocytizing unopsonized particles were not affected by long-term morphine treatment in either Rac1-Q61L– or pcDNA3-transfected cells (Figure 3, C and D). This finding indicates that macroinocytosis is not contributing to morphine’s inhibitory effect and not confounding our conclusion that Rac overexpression rescues morphine’s effect on phagocytosis.

Because constitutive expression of Rac1-GTP overrode morphine’s inhibition of actin polymerization and phagocytosis, we conclude that morphine attenuates actin polymerization by inhibiting Rac1-GTPase activation, thus leading to inhibition of phagocytosis.

### Inhibition of Actin Polymerization by Long-Term Morphine Treatment Is Mediated by cAMP and PKA

We have previously shown that morphine up-regulates cAMP levels in macrophages. Therefore, we investigated cAMP as a potential mechanism by which morphine modulates actin polymerization and phagocytosis. As expected, long-term morphine treatment of macrophage cell line J774 led to a significant increase in cAMP (Figure 4A). To directly observe the effects of elevated cAMP, we used DB-cAMP, a cell-permeable cAMP analog. After a 15-minute incubation with DB-cAMP (100 μmol/L) before the addition of OPDex beads, both actin polymerization (Figure 4B) and...
phagocytosis (Figure 4C) of OPDex beads were inhibited in vehicle and morphine treatments, further indicating that morphine is modulating FcgR phagocytosis via a cAMP-dependent mechanism.

To examine downstream targets of cAMP and their role in this process, we used H89, a known inhibitor of PKA. Pretreating J774 cells with H89 (10 μmol/L) 2 hours before the addition of morphine abolished morphine’s inhibitory effect on actin polymerization (Figure 4B) and phagocytosis of OPDex beads (Figure 4C).

The GLISA assay (Figure 4D) further supports our finding that morphine inhibits Rac-GTPase activation and that it does so in a naltrexone-reversible manner, indicating involvement of classic opioid receptors in inhibition of Rac-GTPase. Furthermore, DB-cAMP treatment of cells before OPDex phagocytosis led to inhibition of Rac-GTPase activity in both morphine- and vehicle-treated cells, as confirmed by the GLISA assay (Figure 4D). In addition, cells pretreated with H89 (previously described) displayed an absence of morphine’s suppression of Rac-GTPase activity in both morphine- and vehicle-treated cells, as confirmed by the GLISA assay (Figure 4D).
GTPase activation, indicating that H89 pretreatment, or inhibition of PKA, abolishes morphine's inhibition of Rac-GTPase activation. Therefore, morphine, through MOR activation, activates adenyl cyclase, increases cAMP, and activates PKA, leading to inhibition of Rac-GTPase activation, actin polymerization, and subsequent phagocytosis.

Inhibition of Actin Polymerization by Long-Term Morphine Is Mediated by p38 MAPK

p38 MAPK is a modulator of actin polymerization downstream of Rac1 and plays an important role in regulation of macrophage phagocytosis. Therefore, morphine modulation of this pathway may be one of the mechanisms by which morphine treatment leads to inhibition of actin polymerization and phagocytosis.

To study if long-term morphine treatment modulates activation of p38 MAPK, J774 cells were pretreated with 10 μmol/L SB203580 (a p38 MAPK inhibitor) for 4 hours before overnight morphine (1 μmol/L) incubation. SB203580 was maintained overnight, along with morphine, followed by OPDex bead treatment for 60 minutes the next day. Western blot analysis (Figure 5A) indicates that phagocytosis of OPDex beads increases phosphorylation of p38 MAPK. Morphine treatment significantly reduced, whereas SB203580 further decreased, phosphorylation of p38 MAPK in both vehicle- and morphine-treated cells. Furthermore, DB-cAMP treatment (previously described) reduced p38 MAPK phosphorylation, indicating that p38 is downstream and that morphine treatment, by increasing intracellular cAMP, leads to inhibition of p38 MAPK. In addition, J774 cells were assessed for actin polymerization (Figure 5B) and phagocytosis (Figure 5D), following the same treatment as previously described. The addition of SB203580 led to inhibition of actin polymerization (Figure 5B) and phagocytosis (Figure 5D). The inhibition of p38 MAPK reduced phagocytic levels to those of cells treated with CytD (20% of control, Figure 2A), indicating strong attenuation of actin polymerization. This highlights the crucial role of p38 MAPK in actin polymerization and phagocytosis. To examine if morphine acts through p38 MAPK to inhibit actin polymerization, we treated cells with anisomycin, a known activator of p38 MAPK. Anisomycin activated p38 MAPK and overrode morphine's inhibition of actin polymerization (Figure 5B) and phagocytosis (Figure 5D). These findings were further confirmed by transfection of constitutively active MKK6 (pcDNA3-Flag.MKK6(GLU)), an upstream activator of p38 MAPK. As expected, the activation of p38 MAPK by transfection of constitutively active MKK6 overrode the inhibitory effect of morphine on actin polymerization (Figure 5C) and phagocytosis (Figure 5E). Taken together, these data indicate that morphine, by inhibiting p38 MAPK phosphorylation, leads to the inhibition of actin polymerization and macrophage pathogen internalization.

To determine whether p38 MAPK is downstream to Rac1, we transfected J774 cells with constitutively active Rac1-Q61L plasmid and treated them with SB203580 before addition of morphine and OPDex beads (previously described). Cells were analyzed for p38 MAPK activation by using Western blot analysis (Figure 5F), whereas phagocytosis (Figure 5G) and actin polymerization (Figure 5H) were quantified using fluorometric analysis. Western blot analysis results (Figure 5F) indicate that p38 MAPK phosphorylation is significantly increased in cells transfected with Rac1-Q61L plasmid in both ve-
hicle- and morphine-treated cells. Rac1-Q61L overexpression overrides morphine-mediated inhibition of p38 MAPK phosphorylation (Figure 5F). Rac1-Q61L transfection also increased levels of total p38 MAPK, while increasing phosphorylated p38 MAPK. Despite the increase in total p38 MAPK, the densitometric ratio of phospho-p38/total p38 was unaltered by morphine in cells transfected with Rac1-Q61L, indicating that constitutive activation of Rac1-GTPase abolishes morphine-mediated inhibition of p38 MAPK activation.

Furthermore, p38 MAPK inhibitor SB 203580 (10 μmol/L) abolished the Rac1-Q61L–induced increase in phagocytosis and actin polymerization (Figure 5, G and H, respectively) in vehicle- and morphine-treated cells, indicating that p38 MAPK is downstream to Rac1-GTPase. Taking these findings into consideration, we conclude that cAMP, by inhibiting Rac1-GTPase, leads to inhibition of p38 MAPK activation and, therefore, inhibition of actin polymerization and phagocytosis.

**Inhibition of Actin Polymerization by Long-Term Morphine Is Not Mediated by ERK1/2**

We next investigated the role of ERK1/2, another MAPK that plays a role in phagocytosis. To study the role of ERK1/2 in morphine’s modulatory pathway, phosphorylation of ERK1/2 was inhibited by PD98059, a known inhibitor of ERK1/2 phosphorylation. Western blot analysis results (Figure 6A) showed that phosphorylation of ERK1/2 was enhanced with the addition of OPDex beads. Morphine treatment inhibited ERK1/2 phosphorylation, similar to PD98059-treated cells. Macrophage pretreatment with 10 μmol/L PD98059 (before the addition of morphine and OPDex beads) led to the inhibition of actin polymerization (Figure 6B) and phagocytosis (Figure 6C) of vehicle but not to morphine-treated macrophages. This can be explained by the fact that morphine already reached maximal inhibition of actin polymerization and, therefore, the additional inhibition of polymerization by PD98059 was not seen in PD98059+ morphine-treated cells. Although morphine alone inhibits phosphorylation of ERK1/2 (Figure 6A), the addition of PD98059 does not further potentiate morphine’s inhibition of phagocytosis, indicating that the mechanism involving ERK1/2 is partially involved in phagocytosis but is not a part of the major modulatory pathway. This was further confirmed by the addition of a known inhibitor of protein phosphatase 2A, calyculin A, which inhibits protein phosphatase 2–mediated dephosphorylation of ERK1/2. By inhibiting ERK1/2 dephosphorylation, calyculin A leads to enhanced ERK1/2 activity. Enhanced ERK1/2 activation via calyculin A (1 nmol/L) pretreatment was not able to abolish morphine-mediated inhibition of actin polymerization and phagocytosis, further supporting our previous conclusion that ERK1/2, although modulated by morphine, does not play a major role in morphine-mediated attenuation of actin polymerization and macrophage phagocytosis.

**Discussion**

This study shows, for the first time to our knowledge, that morphine-induced inhibition of FcgR-mediated phagocytosis occurs through attenuation of actin polymerization by an increase in intracellular cAMP, activation of PKA, inhibition of Rac1-GTPase, and inhibition of p38 MAPK. These findings are supported by several lines of evidence. First, we show that long-term morphine treatment inhibits IgG opsonophagocytosis by inhibiting actin polymerization through a Rac1-GTPase–dependent mechanism. Second, morphine modulates macrophage phagocytic ability and actin polymerization by increasing intracellular cAMP, which activates PKA to inhibit actin...
polymerization by inhibiting activation of Rac1-GTPase and p38 MAPK. Finally, third, overexpression of Rac1-GTPase rescues morphine’s inhibitory effect on p38 MAPK activation, suggesting that Rac1-GTPase is upstream to p38 MAPK.

The prevalence of opioid use extends beyond the drug abuse population to the clinical setting. Morphine-mediated suppression of innate and adaptive immunity is an established phenomenon that is often indicated by an increase in frequency of bacterial infections. Although morphine-mediated immune suppression is well investigated, the mechanisms involved in the modulation of innate immunity are not yet fully understood. Macrophages play an essential role in bacterial clearance, and morphine has been implicated in inhibiting their phagocytic function. Because of the important role that macrophages play in the elimination of pathogens and the significance of deleterious effects caused by the disruption of macrophage homeostasis by opioids, we examined the mechanisms by which morphine modulates key macrophage functions, such as actin polymerization and phagocytosis.

Our results show that morphine treatment in vitro and in vivo inhibits FcgR-mediated phagocytosis in the primary peritoneal and J774 macrophage cell lines. Morphine, through MOR, inhibits actin polymerization and phagocytosis without affecting FcgR expression or cell viability. This indicates that the point of convergence between FcgR and MOR occurs further downstream in the signaling cascade. FcgR-mediated phagocytosis is dependent on actin polymerization and Rac-GTPases that lead to formation of lamellipodia and membrane ruffles. There are three isoforms of Rac (1, 2, and 3) in mammals, but little is known about the relative contributions of each isoform to Rac-dependent responses. We chose to study Rac1 because it is the most extensively studied isoform; in addition, it plays an important part in macrophage phagocytosis. The roles of Rac2 and Rac3 in phagocytosis are not well explored; Rac1 is essential in actin polymerization and dynamics; any modulation of Rac1-GTPase alters downstream functions, such as actin polymerization and phagocytosis. In addition to previous mechanisms, morphine inhibits actin polymerization via inhibition of Rac1-GTPase. This was further confirmed by the observation that overexpression of constitutively activated Rac1-GTPase overrode morphine’s inhibitory effect. We show, for the first time to our knowledge, that morphine causes inhibition of actin polymerization and that it does so by inhibiting activation of Rac1-GTPase. Although Rac1 plays an essential role in macrophage function and cytoskeletal reorganization, it is also involved in many other mechanisms, such as cell growth, vesicle trafficking, and epithelial differentiation, that can potentially be modulated by opioids in other model systems and lead to disruption of homeostasis.

Researchers have correlated long-term morphine-mediated increases in intracellular cAMP to inhibition of phagocytosis. Our research supports findings by Tomei and Renaud, showing that cAMP plays an essential role in morphine-mediated modulation of phagocytosis. Our previously published work and this study, shows that cAMP levels remain elevated after 18 hours of 1 μmol/L morphine treatment and that this increase in cAMP leads to inhibition of phagocytosis. This study adds to the current understanding in the field by implying that a pharmacological increase in cAMP via DB-cAMP leads to a significant decrease in actin polymerization, leading to the attenuation of phagocytosis. Furthermore, inhibition of PKA, via H89, restored activation of Rac1-GTPase, actin polymerization, and phagocytic rates to the baseline level, indicating that cAMP acts through PKA to inhibit Rac1-GTPase activation and, ultimately, actin polymerization and phagocytosis.

The role of PKA and cAMP on modulation of actin polymerization and Rac-GTPase has been controversial. In some systems, such as endothelial cells, activation of PKA inhibits Rac1-GTPase activity, leading to inhibition of endothelial cell migration in vitro and angiogenesis in vivo. cAMP-mediated Rac1-GTP inhibition has also been observed in thyroid cells, and in THP-1 monocyte cell line, in which lipoxins, via elevation of cAMP, lead to inhibition of Rho and Rac GTPases. In addition, several groups have shown that cAMP inhibits Rac-GTPase in serum-induced cell migration, by inhibiting the formation of lamellipodia at the leading edge of migrating fibroblasts or by disrupting cytoskeletal dynamics. Our data show that DB-cAMP inhibits Rac-GTPase, whereas the PKA antagonist, H89, rescues morphine-mediated inhibition of Rac-GTP activation, indicating that, in our model system, elevation of cAMP may be a major player in inhibiting Rac activation. The positive and negative roles of PKA-cAMP in GTPase signaling, cytoskeletal dynamics, and cell migration have been
extensively described in the review by Howe. Considering the literature provided herein, there is evidence to prove that PKA can lead to both activation and inhibition of actin polymerization in multiple cell types and that our model further supports the CAMP-PKA inhibitory role in these processes.

In addition to elevating CAMP, morphine plays an important role in the modulation of MAPKs. Three MAPK cascades have been identified in mammalian cells; the well-characterized MAPK cascade results in the activation of extracellular response kinases or ERKs (ERK1/2, also called p42/p44 MAPK). Opioids have differentially modulated MAPK. Because ERK1/2 and p38 MAPKs may play a role in neutrophil phagocytosis, we examined their role in morphine’s inhibitory effects on macrophage phagocytosis and actin polymerization. Initially, we found that ERK1/2 is involved in the FcgR-mediated actin polymerization and phagocytic pathway. However, the role of ERK1/2 in morphine-mediated inhibition of phagocytosis seemed to be minor because the inhibition of ERK1/2 by PD98059 resulted in inhibition of actin polymerization in vehicle-treated, but not in morphine-treated, cells. Furthermore, the activation of ERK1/2 by calyculin A was unable to abolish morphine’s attenuation of actin polymerization, indicating that ERK1/2 is not involved in the modulatory pathway. On the other hand, our results indicate that morphine inhibits p38 MAPK phosphorylation and that inhibition of p38 MAPK by SB203580 leads to a reduction in phagocytosis. The activation of p38 MAPK by anisomycin or overexpression of MKK6 abolished morphine-mediated inhibition, suggesting that p38 MAPK is essential for this process. Inhibition of p38 MAPK activation had a much more detrimental effect on macrophage phagocytosis than inhibition of ERK1/2, indicating that, although both are involved, p38 MAPK plays a more significant role in FcgR-mediated phagocytic mechanisms.

In the proposed diagram in Figure 7, we depict a summary of the current literature and our findings. Morphine inhibits Rac1-GTPase through activation of CAMP and PKA. Rac-GTPase inhibition negatively regulates p38 MAPK, ultimately leading to decreased actin polymerization and phagocytosis. To our knowledge, this study is the first to propose mechanisms of cross talk between the MOR and FcgR. Our findings are supported by several studies that suggest CAMP leads to inhibition of MAPKs, such as p38 and ERK1/2. However, although a decrease in p38 MAPK is observed after morphine treatment, the effect is antagonized after overexpression of constitutively active Rac1-GTPase. This result implies that the inhibition of p38 MAPK observed in our studies is a consequence of reduced Rac1-GTPase activation and not the result of a parallel inhibitory pathway activated by morphine. These data also support our conclusion that p38 MAPK is downstream from Rac1 and that morphine, by increasing intracellular CAMP and activating PKA, inhibits Rac1-GTPase, leading to inhibition of p38 MAPK directly via inhibition of Rac1-GTPase.

Several groups have examined the role of Rac-GTPases in p38 MAPK activation. p38 MAPK has regulated actin filament formation through the downstream kinases MAPK-APK2/3 or MAPK-APK5 (PRAK), and subsequently through heat-shock protein 25/27. To further our understanding of morphine-mediated inhibition of actin polymerization and phagocytosis, future studies investigating the role of effectors downstream of p38 MAPK in modulating phagocytosis and actin polymerization would be useful.

The significance of our findings presented herein is not limited solely to macrophage phagocytosis, because similar modulations of actin may be occurring in different cell types, resulting in additional deleterious effects, such as inhibition of leukocyte migration and trafficking. Our observations emphasize the broad scope of morphine’s effects on modulation of diverse mechanisms significant to macrophage function. This study highlights several essential pathways of morphine’s immunomodulation that signify the importance and need for discoveries of new therapeutic agents used in pain management that would minimize these immunosuppressive effects.

Acknowledgments

We thank Dr. Subhas Das, Dr. Santanu Banerjee, Dr. Raini Dutta, and Haidong Yu for their technical advice and support.

References

51. Howe AK: Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys Acta 2004, 1692:159–174